Is Arvee Laboratories India the Best Stock in Its Sector? A Look at the Numbers

Arvee Laboratories India CMP Rs 236 (23 Sep 2026). Market cap Rs 260 Cr. ROE 7.48%. P/E 64.15x versus Industry P/E 40.34x.

Updated: 23 Sept 2026 • 11:11 am

Posted by:

Is Arvee Laboratories India the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Arvee Laboratories India is one of the names investors compare when screening the Healthcare sector, built on a 7.48% return on equity and a P/E of 64.15x against an Industry P/E of 40.34x. Whether Arvee Laboratories India is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Arvee Laboratories India the best stock in its sector? The stock trades on the NSE at Rs 236 as of 23 September 2026, within its 52-week range of Rs 129.11 to Rs 290.78. Arvee Laboratories (India) Ltd manufactures nutraceutical and pharmaceutical formulations.

Arvee Laboratories India sits in the Healthcare sector, and its 7.48% ROE and 64.15x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

About Arvee Laboratories India

Arvee Laboratories (India) Ltd manufactures nutraceutical and pharmaceutical formulations. It manufactures nutraceutical and pharmaceutical formulations, a smaller-scale operation than the larger API and CDMO peers it is compared against here. At a market capitalisation of Rs 260 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Arvee Laboratories India the Best Stock in Its Sector?

Arvee Laboratories India makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 7.48% ROE with a 64.15x P/E against the sector's 40.34x Industry P/E. Arvee Laboratories' 64.15x P/E is above the 40.34x Industry P/E despite a 7.48% ROE that trails Alpa Laboratories and Anuh Pharma in this series, so the valuation leans on growth expectations rather than current returns.

Metric	Arvee Laboratories India
CMP (NSE)	Rs 236.07
52-Week High / Low	Rs 290.78 / Rs 129.11
Market Cap	Rs 260 Cr
P/E (TTM) vs Industry P/E	64.15x vs 40.34x
P/B	7.70
ROE	7.48%
EPS (TTM)	Rs 3.68
Dividend Yield	0.00%
Debt to Equity	0.03

Compare Arvee Laboratories India Against Other Healthcare Sector Stocks

How Arvee Laboratories India Compares Against Its Healthcare Sector Peers

The table below sets Arvee Laboratories India against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Arvee Laboratories India	260	64.15	7.48%	0.03
Alpa Laboratories	128	31.43	8.06%	0.01
Anuh Pharma	942	21.32	11.65%	0.00
Peer average (2 companies)	-	26.38	9.86%	0.01

Against this peer set, Arvee Laboratories India's 7.48% ROE is below the 9.86% peer average, and its P/E of 64.15x runs above the peer average of 26.38x. Arvee Laboratories' 64.15x P/E is above the 40.34x Industry P/E despite a 7.48% ROE that trails Alpa Laboratories and Anuh Pharma in this series, so the valuation leans on growth expectations rather than current returns.

What Makes Arvee Laboratories India Worth Watching in Healthcare

Near debt free: A debt to equity ratio of 0.03 gives Arvee Laboratories significant balance sheet flexibility.
Nutraceutical and pharma formulation focus: Manufacturing both nutraceutical and pharmaceutical formulations gives Arvee Laboratories exposure to two related but distinct product categories.
Rich valuation versus current ROE: A 64.15x P/E against a 7.48% ROE is high for the current return profile, above the 40.34x Industry P/E.

Arvee Laboratories India Valuation: Is It Justified?

Arvee Laboratories' 64.15x P/E is above the 40.34x Industry P/E despite a 7.48% ROE that trails Alpa Laboratories and Anuh Pharma in this series, so the valuation leans on growth expectations rather than current returns. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Anthem Biosciences the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Arvee Laboratories India and other Healthcare sector stocks.

How to Track Arvee Laboratories India Before You Invest

Before deciding whether Arvee Laboratories India deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Arvee Laboratories India to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Arvee Laboratories India earns a place in the best stock in its sector conversation on the strength of a 7.48% ROE and a P/E of 64.15x against a 40.34x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Arvee Laboratories India the best stock in its sector?

Ans. Arvee Laboratories India has a 7.48% ROE and trades at 64.15x P/E against a 40.34x Industry P/E, and compares below the peer average ROE of 9.86% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Arvee Laboratories India?

Ans. Arvee Laboratories India was trading at Rs 236.07 on the NSE as of 23 September 2026, within its 52-week range of Rs 129.11 to Rs 290.78.

What sector does Arvee Laboratories India belong to?

Ans. Arvee Laboratories India is classified under the Healthcare sector on Univest.

How does Arvee Laboratories India compare to its sector peers on P/E?

Ans. Arvee Laboratories India's P/E of 64.15x is above the 26.38x average of the 2 named peers compared in this article.

What is Arvee Laboratories India's return on equity?

Ans. Arvee Laboratories India reported a return on equity of 7.48%, which is below the 9.86% average of its named peers in this comparison.

Should I invest in Arvee Laboratories India based on its sector position?

Ans. Arvee Laboratories India's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.